NTT
9.11.2021 10:02:13 CET | Business Wire | Press release
NTT Ltd. , a global technology and business solutions provider, today releases the 2021 edition of the Global Workplace Report , providing vital insight into the future of work as businesses around the world prepare for a post-pandemic reality. The report finds that business leaders are significantly more satisfied with how they have adjusted to new working norms than their employees are, and points to the need for clearer organizational insight into how employees have reevaluated what they need from their workplace.
Shared awareness, divergent outlooks
Conducting 1,146 interviews across 23 countries, NTT found near-universal agreement that remote working has introduced difficulties, with 82% of respondents saying that it has challenged organizational performance and 81% saying that it has been challenging for employees. 63% of CHROs, meanwhile, say that employee wellbeing has deteriorated over the course of the pandemic.
Broad awareness of the issue is not always translating into a realistic assessment of organizational capability, however. Compared to operations staff, CEOs are 20 percentage points more likely to believe that their organization is very effective at managing working hours, 28 points more likely to believe that they are effective at preventing burnout, and 41 points more likely to be very satisfied with their organization’s employee experience (EX) capabilities.
This awareness gap mirrors a serious lack of employee confidence, with just 38% saying that their employer fully values their health and wellbeing and only 23% saying they are very happy working for their employer.
The great work-life reassessment
Underlying the satisfaction gap between employers and employees, the research found a significant degree of diversity in employee attitudes towards their own future working preferences. Voice of the Employee (VoE) data shows that, when offered a choice of at-home, hybrid, or in-office working arrangements, employees are relatively evenly split between the three, at 30%, 30%, and 39%, respectively.
This finding contradicts the belief, shared by 79% of organizations, that employees prefer office working – when in fact, VoE data finds that just 39% of employees desire full-time office working.
“Currently, the narrative is all about remote working – but the reality of employees’ needs is much more complicated, and any failure to accurately assess and respond to that fact presents a serious risk to organizations”, comments Alex Bennett, Global Senior Vice President, GTM Solutions at NTT Ltd. “These are not mild preferences: we found that work-life balance and commute times are now the two biggest factors people look at when deciding where to work, and so performing well on workforce and workplace strategy will be a real competitive advantage.”
The need to lead by EXample
Acting based on a clear view of employees’ outlooks is being made more difficult by a lack of thorough data and insight collection. In terms of data priorities, 52% of businesses report VoE being a top focus, second only to workplace analytics at 54%. Despite this, however, just 39% of organizations have structured VoE programs, and 37% employ real-time sentiment analysis, compared to 54% utilizing employee surveys.
The research also demonstrated that the application of these kinds of data for improving an organization’s EX needs to go much further than day-to-day quality-of-life improvements; at 40%, a company’s purpose and values is now the third most important factor for choosing where to work. In this area, employees and business leaders are in sync, with 89% agreeing that environment, social and, governance (ESG) objectives are at the heart of the organization’s agenda.
“I would look at this as a call to shift our thinking from being about actions to being about outcomes,” concludes Bennett. “What’s important is not what we do to improve the workplace, but how it actually benefits the workforce – and an organization cannot know that without a mature approach to measuring employees’ sentiment. Surprisingly, two thirds of employees say they’re not yet equipped with all the tools they need to work from home, and just 55% of organizations say they are strongly satisfied that office spaces are ready for hybrid working. Nonetheless, 82% of organizations are engaged in reshaping their office space over the next 12 months to foster an environment of innovation and social connection. Clearly, there’s an awareness on some level that immature workforce strategies will lead to employee discontent and that work should be led by what people actually need.”
–ENDS–
About NTT Ltd.
NTT Ltd. is a leading global technology services company. Working with organizations around the world, we achieve business outcomes through intelligent technology solutions. For us, intelligent means data driven, connected, digital and secure. Our global assets and integrated ICT stack capabilities provide unique offerings in cloud-enabling networking, hybrid cloud, data centers, digital transformation, client experience, workplace and cybersecurity. As a global ICT provider, we employ more than 40,000 people in a diverse and dynamic workplace that spans 57 countries, trading in 73 countries and delivering services in over 200 countries and regions. Together we enable the connected future.
Visit us at hello.global.ntt
View source version on businesswire.com: https://www.businesswire.com/news/home/20211109005742/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
IMPACT Therapeutics and Pharmanovia Announce Positive CHMP Opinion for Senaparib, as a Potential First-Line Maintenance Treatment of Advanced High-Grade Epithelial Ovarian, Fallopian Tube, and Primary Peritoneal Cancer18.9.2026 12:38:00 CEST | Press release
For business and medical media only This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918325771/en/ Stephan Eder, CEO, Pharmanovia IMPACT Therapeutics (07630.HK), a commercial-stage biotechnology company focused on the discovery and development of targeted anti-cancer therapeutics based on synthetic lethality mechanisms, together with global specialty pharmaceutical company Pharmanovia, today jointly announce that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive opinion recommending the granting of a Marketing Authorisation (MA) for the medicinal product Sepalna® (senaparib) intended for the maintenance treatment of advance epithelial ovarian, fallopian tube and primary peritoneal cancer. Following the CHMP’s recommendation for approval, senaparib will be submitted to the European Commission (EC) for final decision. Once approved by the EC, senaparib will
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom
